

PRKAR1A (protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1))


Identity

Other names
R1A
CAR
CNC1
MGC17251
PKR1
PRKAR1
TSE1

Hugo
[PRKAR1A](#)

Location
 17q23-24

DNA/RNA



Description The RI alpha gene is composed of 10 coding exons of varying lengths, separated by introns, giving the gene a total length of at least 21 kb.

Transcription By alternative splicing, the PRKAR1A gene encodes 3 types of transcripts that all translate in the same protein.

Protein

Description 48 kDa ; contains two tandem cAMP-binding domains at the C-terminus and the dimerization domain at the N-terminus that serves also as a docking site for A Kinase Anchoring Proteins (AKAPs).

Expression Ubiquitously expressed, in particular in brain, endocrine tissues, adipose tissue and bone.

Localisation Predominantly cytoplasmic; nuclear traslocation possible.

Function Two regulatory subunits bind to two catalytic subunits forming an heterotetramer, the inactive holoenzyme protein kinase A (PKA) or cyclic AMP-dependent protein kinase. PKA activation occurs when 2 cAMP molecules bind to each regulatory subunit, eliciting a reversible conformational change that releases the now active catalytic subunits. Four different regulatory subunits and three catalytic subunits of PKA have been identified in humans. The protein encoded by PRKAR1A is

just one of the four possible regulatory subunits of the PKA tetramer; however, PRKAR1A is the most abundant and widely expressed PKA subunit. Although its other functions are not fully elucidated yet, PRKAR1A may act as a tumor-suppressor gene in [Carney complex \(CNC\)](#) and in sporadic (non-CNC-related) adrenal and thyroid tumors.

Homology Prkar1a, Mus musculus
Gene conserved in Mammalia: M.musculus-81.36%; R.norvegicus-97.38%; C.elegans-57.91%; D.melanogaster-72.07%; S. cerevisiae-37.41%

Mutations

Germinal Most mutations are null alleles; they are dispersed throughout the coding region of the gene.

Somatic Many of tumors that develop in patients with Carney complex and PPNAD (see below) show loss of heterozygosity; somatic mutations in the PRKARIA gene have been reported in three cases of sporadic adrenocortical tumors.

Implicated in

Entity [Carney complex syndrome, type I](#)

Disease A multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, psammomatous melanotic schwannomas and some other tumors.

Prognosis According to the severity of the disease in a given patient, and to the quality of a regular follow up; life span is decreased in patients with CNC. 57% of the deaths are due to heart related causes; others due to the postoperative complications or evolution of the malignant process; presymptomatic diagnosis improves survival data and might prevent earlier the main causes of death in this disease.

Cytogenetics Limited data; some of myxomas and PPNAD from CNC patients showed telomeric associations, dicentric chromosomes, aneuploidy, polyploidy and chromosomal rearrangements.

Hybrid/Mutated Gene Half of CNC patients show PRKARIA mutations.

Oncogenesis PRKARIA is frequently affected by bi-allelic inactivation in tumors of CNC patients. However 1 kindred was described where a splice site mutation led to exon 6 skipping and an expressed shorter PRKAR1A protein. The mutant protein was present in patients' leukocytes and tumors, and in vitro studies indicated that the mutant PRKAR1A activated cAMP-dependent PKA signaling at the nuclear level. Along with the lack of allelic loss at the PRKAR1A locus in most of the tumors from this kindred, these data suggested that alteration of PRKAR1A function, not only its complete loss, is sufficient for augmenting PKA activity leading to tumorigenesis in tissues in patients with CNC.

Entity **PPNAD - Primary pigmented nodular adrenocortical disease**
Primary pigmented nodular adrenocortical disease

Disease PPNAD is a cause of ACTH-independent Cushing's syndrome. This condition can be difficult to diagnose because hypercortisolism may be periodic and adrenal imaging may not demonstrate an adrenal tumor.

Hybrid/Mutated Gene Inactivating PRKAR1A germline mutations are frequent in sporadic and isolated cases of PPNAD.
 Oncogenesis Both alleles are frequently inactivated. The wild-type allele can be inactivated by somatic mutations, consistent with the hypothesis of the gene being a tumor suppressor gene.

Entity [Adrenocortical tumors, sporadic](#)

Disease Patients frequently present with ACTH-independent Cushing's syndrome.

Hybrid/Mutated Gene Somatic mutations in the PRKAR1A gene were identified in 3 cases of sporadic adrenocortical tumor. All 3 mutations predicted premature termination of the protein. 17q23-24 loss-of-heterozygosity is a frequent event in adrenal carcinomas.

Oncogenesis Haploinsufficiency of PRKARIA and a reversal of the ratio of R1A to R2B have been proposed to cause tumorigenesis, at least in some cases.

Entity **Myxoma, intracardiac**

Disease Benign neoplasms that occur in 7 per 10,000 individuals. These slowly proliferating lesions arise from subendocardial pluripotent primitive mesenchymal cells, which can differentiate within myxomas along a variety of lineages including epithelial, hematopoietic, and muscular.

Prognosis Life span is decreased in patients with myxomas. Morbidity and mortality are the result of embolic stroke, heart failure due to intracardiac obstruction, and rheumatologic symptoms attributed to myxoma-mediated production of IL-6.

Cytogenetics Limited data; 15 cases of myxomas contained clonal numerical and structural abnormalities including telomeric associations.

Hybrid/Mutated Gene Mutations of PRKARIA detected in the coding region of the gene, exons 5, 7 and 8.

Oncogenesis No somatic mutations were detected in cardiac myxomas; haploinsufficiency of PRKARIA and a reversal of the ratio of RIA to R2B have been proposed may contribute in tumorigenesis.

Entity [Papillary thyroid carcinoma](#)

Cytogenetics Reciprocal translocation between chromosomes 10 and 17

Hybrid/Mutated Gene [RET](#)/PTC2 is formed by the fusion of the RET tyrosine kinase domain with part of the RI-alpha regulatory subunit

Abnormal Protein RET/PTC2

Oncogenesis The fusion of the RET tyrosine kinase domain with a portion of the RIA gene leads to the expression of RET in the thyroid cells, where it is normally transcriptionally silent.

External links

Nomenclature

[Hugo](#) [PRKAR1A](#)

[GDB](#) [PRKAR1A](#)

[Entrez Gene](#) [PRKAR1A 5573](#) protein kinase, cAMP-dependent, regulatory, type I,

alpha (tissue specific extinguisher 1)

Cards

[Atlas](#)
[GeneCards](#)
[Ensembl](#)
[CancerGene](#)
[Genatlas](#)
[GeneLynx](#)
[eGenome](#)
[euGene](#)

[PRKAR1AID387](#)

[PRKAR1A](#)
[PRKAR1A](#)
[PRKAR1A](#)
[PRKAR1A](#)
[PRKAR1A](#)
[PRKAR1A](#)
[5573](#)

Genomic and cartography

[GoldenPath](#)

[PRKAR1A](#) - [chr17:64020138-64040503](#) + [17q24.2](#) (hg17-May_2004)

[Ensembl](#)

[PRKAR1A - 17q24.2 \[CytoView\]](#)

[NCBI](#)

[Genes Cyto](#) [Gene Seq](#) [Map View - NCBI]

[OMIM](#)

[Disease map \[OMIM\]](#)

[HomoloGene](#)

[PRKAR1A](#)

Gene and transcription

[Genbank](#)

[AF411298](#) [SRS] [AF411298](#) [ENTREZ]

[Genbank](#)

[AA015682](#) [SRS] [AA015682](#) [ENTREZ]

[Genbank](#)

[AI074326](#) [SRS] [AI074326](#) [ENTREZ]

[Genbank](#)

[AK097580](#) [SRS] [AK097580](#) [ENTREZ]

[Genbank](#)

[AK124586](#) [SRS] [AK124586](#) [ENTREZ]

[RefSeq](#)

[NM_002734](#) [SRS] [NM_002734](#) [ENTREZ]

[RefSeq](#)

[NM_212471](#) [SRS] [NM_212471](#) [ENTREZ]

[RefSeq](#)

[NM_212472](#) [SRS] [NM_212472](#) [ENTREZ]

[RefSeq](#)

[NT_086886](#) [SRS] [NT_086886](#) [ENTREZ]

[AceView](#)

[PRKAR1A](#) AceView - NCBI

[TRASER](#)

[PRKAR1A](#) Traser - Stanford

[Unigene](#)

[Hs.280342](#) [SRS] [Hs.280342](#) [NCBI] [HS280342](#) [spliceNest]

Protein : pattern, domain, 3D structure

[SwissProt](#)

[P10644](#) [SRS] [P10644](#) [EXPASY] [P10644](#) [INTERPRO]

[Prosite](#)

[PS00888 CNMP_BINDING_1](#) [SRS] [PS00888 CNMP_BINDING_1](#) [Expasy]

[Prosite](#)

[PS00889 CNMP_BINDING_2](#) [SRS] [PS00889 CNMP_BINDING_2](#) [Expasy]

[Prosite](#)

[PS50042 CNMP_BINDING_3](#) [SRS] [PS50042 CNMP_BINDING_3](#) [Expasy]

[Interpro](#)

[IPR002373 cAMP_kin](#) [SRS] [IPR002373 cAMP_kin](#) [EBI]

[Interpro](#)

[IPR000595 cNMP_binding](#) [SRS] [IPR000595 cNMP_binding](#) [EBI]

[Interpro](#)

[IPR003117 RIIa](#) [SRS] [IPR003117 RIIa](#) [EBI]

[CluSTr](#)

[P10644](#)

[Pfam](#)

[PF00027 cNMP_binding](#) [SRS] [PF00027 cNMP_binding](#) [Sanger]
] [pfam00027](#) [NCBI-CDD]

[Pfam](#)

[PF02197 RIIa](#) [SRS] [PF02197 RIIa](#) [Sanger] [pfam02197](#) [NCBI-CDD]

[Smart](#)

[SM00100 cNMP](#) [EMBL]

[Smart](#)

[SM00394 RIIa](#) [EMBL]

[Blocks](#)

[P10644](#)

Polymorphism : SNP, mutations, diseases

[OMIM](#)

[188830](#) [map]

[GENECLINICS](#)

[188830](#)

[SNP](#) [PRKAR1A](#) [dbSNP-NCBI]
[SNP](#) [NM_002734](#) [SNP-NCI]
[SNP](#) [NM_212471](#) [SNP-NCI]
[SNP](#) [NM_212472](#) [SNP-NCI]
[SNP](#) [PRKAR1A](#) [GeneSNPs - Utah] [PRKAR1A](#) [SNP - CSHL] [PRKAR1A](#) [HGBASE - SRS]

General knowledge

[Family Browser](#) [PRKAR1A](#) [UCSC Family Browser]
[SOURCE](#) [NM_002734](#)
[SOURCE](#) [NM_212471](#)
[SOURCE](#) [NM_212472](#)
[SMD](#) [Hs.280342](#)
[SAGE](#) [Hs.280342](#)
[Amigo](#) [function|3',5'-cAMP binding](#)
[Amigo](#) [component|cAMP-dependent protein kinase complex](#)
[Amigo](#) [function|cAMP-dependent protein kinase regulator activity](#)
[Amigo](#) [process|intracellular signaling cascade](#)
[Amigo](#) [process|protein amino acid phosphorylation](#)
[Amigo](#) [process|regulation of transcription from Pol II promoter](#)
[BIOCARTA](#) [Activation of cAMP-dependent protein kinase, PKA](#)
[PubGene](#) [PRKAR1A](#)

Other databases

Probes

[Probe](#) [PRKAR1A Related clones \(RZPD - Berlin\)](#)

PubMed

[PubMed](#) [40 PubMed reference\(s\) in LocusLink](#)

Bibliography

The tissue-specific extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent protein kinase.

Boshart M, Weih F, Nichols M, Schutz G.
Cell 1991; 66: 849-859.
Medline [1832337](#)

Subtractive hybridization cloning of a tissue-specific extinguisher: TSE1 encodes a regulatory subunit of protein kinase A.

Jones KW, Shapero MH, Chevrette M, Fournier REK.
Cell 1991; 66: 861-872.
Medline [1889088](#)

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E., Mondellini P, Della Porta G, Pierotti MA.
Molec Cell Biol 1993; 13: 358-366.
Medline [7678053](#)

Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.

Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti MA.

Cancer Res 1994; 54(11):2979-2985.
Medline [8187085](#)

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinoma.

Grieco M, Santoro M, Berlingieri MT.
Cell 1994; 60: 557-563.
Medline [2406025](#)

Identification of a novel genetic locus for familial cardiac myxomas and Carney complex.

Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE, Denio AE, Korf B, Irvine AD, Hughes A, Carney JA, Stratakis CA, Basson CT.
Circulation 1998; 98: 2560-2566.
Medline [9843463](#)

RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas.

Learoyd DL, Messina M, Zedenius J, Guinea AI, Delbridge JLW, Robinson BG.
Clin Endocrinol Metab 1998; 83(10): 3631-3635.
Medline [9768676](#)

Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex.

Casey M, Vaughan CJ, He J, Hatcher CJ, Winter JM, Weremowicz S, Montgomery K, Kucherlapati R, Morton CC, Basson CT.
J Clin Invest 2000; 106(5): R31-38.
Medline [10974026](#)

Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex.

Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA.
Hum Mol Genet 2000; 9: 3037-3046.
Medline [11115848](#)

Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA.
Nat Genet 2000; 26: 89-92.
Medline [10973256](#)

Perspective: lessons learned from molecular genetic studies of thyroid cancer- insights into pathogenesis and tumor-specific therapeutic targets.

Fagin J.
Endocrinology 2002; 143(6): 2025-2028.
Medline [12021165](#)

Molecular analysis of the cyclic AMP - dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney Complex and

primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.

Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J.

Am J Hum Genet 2002; 71: 1433-1442.

Medline [12424709](#)

High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas.

Lam KY, Lo CY, Leung PS.

Eur J Endocrinol 2002; 147(6): 741-745.

Medline [12457448](#)

PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex.

Sandrini F, Kirschner LS, Bei T, Farmakidis C, Yasufuku-Takano J, Takano K, Prezant TR, Marx SJ, Farrell WE, Clayton RN, Groussin L, Bertherat J, Stratakis CA. J Med Genet 2002; 39(12): e78.

Medline [12471216](#)

Regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer.

Sandrini F, Matyakhina L, Sarlis NJ, Kirschner LS, Farmakidis C, Gimm O, Stratakis CA.

Genes Chromosomes Cancer 2002; 35: 182-192.

Medline [12203783](#)

Molecular mechanisms of RET activation in human cancer.

Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G.

Ann NY Acad Sci 2002; 963: 116-121.

Medline [12095936](#)

Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.

Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis CA.

Cancer Res 2003; 63: 5308-5319.

Medline [14500362](#)

[REVIEW articles](#) *automatic search in PubMed*

[Last year publications](#) *automatic search in PubMed*

[BiblioGene - INIST](#)

[Contributor\(s\)](#)

Written 10-2004 Constantine A Stratakis, Ludmila Matyakhina

[Citation](#)

This paper should be referenced as such :

Stratakis CA, Matyakhina L . PRKAR1A (protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1)). Atlas Genet Cytogenet Oncol Haematol. October 2004 .

URL : <http://www.infobiogen.fr/services/chromcancer/Genes/PRKAR1AID387.html>

© *Atlas of Genetics and Cytogenetics in Oncology and Haematology*
